Snapshot from May 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Knight Therapeutics
Company

Knight Therapeutics

Tracked across 2 events · 12 articles · First seen Mar 31, 2026 · Last active May 28, 2026

Sentiment
20
Attention
4
Events
2
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (2)
4 40
Business
PatentVest Report on Obesity Drug IP
PatentVest, a division of MDB Capital Holdings, released a comprehensive report titled 'The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market' on May 8, 2026. The report analyzes…
Impact: Knight Therapeutics is identified as an emerging player in the development of next-generation obesity therapeutics.
May 08, 2026 · 6 articles
2 0
Business
Ardelyx Appoints Rajani Dinavahi CMO
Impact: Knight Therapeutics commercializes IBSRELA in Canada, a product developed by Ardelyx.
Apr 01, 2026 · 6 articles
Relationships (2)
United States — Food and Drug Administration ↔ Knight Therapeutics
United States — Food and Drug Administration ↔ Knight Therapeutics
NEWSDESK
Track Knight Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.